The Senate just drew a line in the sand.
A draft continuing resolution, set to fund the government until December 11, would effectively pause the Office of Management and Budget’s (OMB) controversial attempt to rewrite the rules of scientific grant funding. If this bill passes, the current peer-review system remains intact for the next three months.
This isn’t about stopping the OMB’s plan forever. It’s about buying time.
The proposed rule would shift power away from independent panels of expert scientists. Instead, political appointees would get the final say on which research gets federal money. The logic? Streamlining. The reality? Politicizing basic science.
Scientists were not pleased. They rushed to submit half a million comments during the public period, which ended in July 13. The backlash was immediate and severe. Nobel laureates joined the fray, warning that this power grab would damage U.S. innovation. They argued that letting bureaucrats pick winners and losers based on political alignment is a dangerous path.
The Fight to Keep Science Apolitical
Representative Rosa DeLauro (D-CT) knows the stakes. As ranking member of the House Appropriations Committee, she called the bill’s pause a temporary victory, not a final one.
“While the bill temporarily blocks the proposed OMB rule the fight must continue.”
DeLauro argues that the Senate bill forces the OMB to keep reviewing those half-million public comments. But stopping the clock isn’t enough. She wants Congress to permanently block what she calls a “corrupt, harmful power grab” before the December 11 deadline expires.
The OMB’s rule would hand control of agencies like the National Institutes of Health (NIH) and the National Science Foundation (NSF) to political insiders. The current system relies on merit-based peer review. Experts in the field evaluate proposals. It’s slow. It’s bureaucratic. But it’s also largely immune to political winds.
Who is Opposing the Rule Changes?
It’s not just academics crying foul. Senator Susan Collins (R-ME), chair of the Senate Appropriations Committee, backed the pause. She has been vocal about the dangers of the OMB’s proposal since a July 6 letter.
“I advocated for significant changes to the Proposed rule… citing its potential to politicize Grants and harm small, rural communities.”
Collins sees two distinct risks here. First, the politicization of the grants process. Second, the tangible impact on rural communities and families who rely on biomedical research funding. By stalling the rule, the Senate is ensuring that these specific concerns are part of the ongoing dialogue.
The OMB claims these changes are necessary for efficiency. Critics say efficiency shouldn’t come at the cost of scientific integrity. When political appointees override peer reviewers, the focus shifts from “what works” to “what aligns with current administration goals.” That is a fragile foundation for long-term research.
What Happens Next?
The continuing resolution is just a bridge. It extends funding and keeps the old rules in place until mid-December. But once that date hits, the OMB’s new rule could take effect unless Congress acts again.
The question isn’t just how this bill moves through the House. It’s whether the pressure from scientists, lawmakers, and the public will force a permanent halt.
If the OMB rule stands, we enter a new era where science funding is a political tool. If it fails, we preserve a system built on expertise.
Right now, we have a pause button. But the game is far from over.
